Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis

The S100B protein is associated with brain damage and a breached blood–brain barrier. A previous pilot study showed that high serum levels of S100B are associated with shorter survival in glioma patients. The aim of our study was to assess the prognostic value in terms of survival and longitudinal d...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2016-09, Vol.129 (3), p.525-532
Main Authors: Holla, F. K., Postma, T. J., Blankenstein, M. A., van Mierlo, T. J. M., Vos, M. J., Sizoo, E. M., de Groot, M., Uitdehaag, B. M. J., Buter, J., Klein, M., Reijneveld, J. C., Heimans, J. J.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antineoplastic Agents, Alkylating - therapeutic use
Brain Neoplasms - blood
Brain Neoplasms - drug therapy
Clinical Study
Dacarbazine - analogs & derivatives
Dacarbazine - therapeutic use
Female
Glioma - blood
Glioma - drug therapy
Humans
Kaplan-Meier Estimate
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Recurrence, Local - metabolism
Neurology
Oncology
Retrospective Studies
S100 Proteins - blood
Statistics, Nonparametric
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The S100B protein is associated with brain damage and a breached blood–brain barrier. A previous pilot study showed that high serum levels of S100B are associated with shorter survival in glioma patients. The aim of our study was to assess the prognostic value in terms of survival and longitudinal dynamics of serum S100B for patients with newly diagnosed and recurrent glioma. We obtained blood samples from patients with newly diagnosed and recurrent glioma before the start (baseline) and at fixed time-points during temozolomide chemotherapy. S100B-data were dichotomized according to the upper limit of the reference value of 0.1 μg/L. Overall survival (OS) was estimated with Kaplan–Meier curves and groups were compared with the log rank analysis. To correct for potential confounders a Cox regression analysis was used. We included 86 patients with newly-diagnosed and 27 patients with recurrent glioma. Most patients in both groups had baseline serum levels within normal limits. In the newly diagnosed patients we found no significant difference in OS between the group of patients with S100B levels >0.1 μg/L at baseline compared to those with
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-016-2204-z